Condition (MeSH)
Hereditary Angioedema Type III
ClinicalTrials.gov lists 3 trials for Hereditary Angioedema Type III or a narrower condition beneath it. Pharvaris Netherlands B.V. has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
3 of the 3 trials are tagged with Hereditary Angioedema Type III itself; the rest are tagged with a narrower condition beneath it.
When did Hereditary Angioedema Type III trials start? (3)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2/3
- Phase 3
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2022 | 1 |
| 2018 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hereditary Angioedema Type III trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Observational | 1 |
How many Hereditary Angioedema Type III trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Enrolling by invitation | 1 |
| Completed | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hereditary Angioedema Type III trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pharvaris Netherlands B.V. | 2 |
| CENTOGENE GmbH Rostock | 1 |
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| F12-related hereditary angioedema with normal C1Inh | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| F12-related hereditary angioedema with normal C1Inh | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| F12-related hereditary angioedema with normal C1Inh | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| F12-related hereditary angioedema with normal C1Inh | 100054 | Exact | Orphadata Science knowledge files, Product 1 |
| F12-related hereditary angioedema with normal C1Inh | 100054 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, publications, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.